GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Kilitch Drugs India Ltd

Kilitch Drugs to divest Ethiopian subsidiary for USD 12.86 million

MANAGEMENT ▲ Positive Development LOW RISK
📅 Filed on BSE: 22 Oct 2026, 08:18 PM IST  ·  BSE ID: 00d21523-f47c-4f59-8312-feef16dd327d
View Original BSE Filing (PDF)
💡
In Simple Terms
The company is selling its stake in an overseas subsidiary and converting debt into shares for that business.
🤖 AI Summary
  • Kilitch Drugs to sell entire stake in subsidiary Kilitch Estro Biotech PLC.
  • Divestment consideration due to the Company is USD 12,855,000.
  • INR 57.00 Crores outstanding debt to subsidiary converted to equity.
  • HarmeeCare Pharmaceuticals is the buyer of the Ethiopian subsidiary.
  • Appointment of an Additional Independent Non-Executive Director approved.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Divestment Consideration (Company's Share)
USD 12,855,000
Aggregate Consideration Payable by Buyer
USD 14,000,000
Outstanding Debt Converted to Equity
INR 57.00 Crores
🏢 How This Affects the Company
📈
Business Impact
The divestment of the Ethiopian subsidiary will alter the company's geographical footprint and business operations.
💰
Financial Impact
The company will receive USD 12,855,000 from the divestment, impacting its cash and investments. Conversion of INR 57.00 Crores debt into equity will impact its balance sheet.
⚠️
Risk Impact
Exiting an international subsidiary may reduce geopolitical and operational risks associated with that specific market.
👥 What This Means For Shareholders
✅
Action Required
No action is required by shareholders regarding this board decision.
👤
Who Is Affected
All shareholders are affected by the strategic decision to divest a subsidiary, impacting the company's asset base.
🔍
Management Signal
Management is demonstrating intent to streamline operations and monetize international assets.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Completion of the divestment transaction with HarmeeCare Pharmaceuticals.
Update on the utilization of the USD 12,855,000 divestment proceeds.
Information on the newly appointed Additional Independent Non-Executive Director.
LOW RISK The filing details a finalized board resolution for divestment and debt conversion.
💡 Investor Takeaway
Kilitch Drugs will receive USD 12,855,000 from selling its Ethiopian subsidiary, with INR 57.00 Crores debt to the subsidiary converted to equity.
⚖️ Strengths & Concerns

✅ Positives

  • Successful divestment of an overseas subsidiary for a defined cash consideration of USD 12,855,000.
  • Conversion of outstanding debt of INR 57.00 Crores into equity prior to divestment.
❓ Frequently Asked Questions
What is the value of Kilitch Drugs' divestment of Kilitch Estro Biotech PLC?
Kilitch Drugs will receive USD 12,855,000 from the divestment of its entire shareholding in Kilitch Estro Biotech PLC.
How much debt is Kilitch Drugs converting into equity for its subsidiary?
Kilitch Drugs is converting INR 57.00 Crores of outstanding debt extended to Kilitch Estro Biotech PLC into equity shares.
Who is the buyer of Kilitch Drugs' Ethiopian subsidiary?
HarmeeCare Pharmaceuticals, a state-owned public enterprise of the Oromia Regional State of Ethiopia, is the buyer.
What was the total consideration for the sale of Kilitch Estro Biotech PLC?
The aggregate consideration payable by the buyer for 100% shareholding of KEB is USD 14,000,000.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.